Hilltop Holdings Inc. Acquires 6,719 Shares of Abbott Laboratories $ABT

Hilltop Holdings Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 226.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,681 shares of the healthcare product maker’s stock after purchasing an additional 6,719 shares during the quarter. Hilltop Holdings Inc.’s holdings in Abbott Laboratories were worth $994,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the 4th quarter worth approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Mizuho decreased their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Wednesday, April 22nd. Benchmark decreased their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Citigroup boosted their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Finally, The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Stock Performance

ABT stock opened at $103.13 on Monday. The business’s fifty day simple moving average is $91.61 and its two-hundred day simple moving average is $101.16. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a market cap of $179.63 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the business posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.